Lys Therapeutics, a biotechnology company dedicated to developing first-in-class biologics for patients with neurovascular or neurodegenerative disorders. The company’s lead program involves an anti-GluN1 monoclonal antibody, targeting blood-brain barrier dysfunction and associated neuroinflammation and neurodegeneration. This groundbreaking drug candidate, developed by Lys Therapeutics, specifically blocks the interaction between tissue plasminogen activator (tPA) and NMDA receptors, preventing neuroinflammation, neurotoxicity, and blood-brain barrier disruption while restoring NMDA receptor functioning.